BridgeBio Pharma (BBIO) Non Operating Interest Expenses (2018 - 2026)

For the trailing twelve months through Jun 30, 2026, Non Operating Interest Expenses at BridgeBio Pharma was $49.6 million, down 33.3% year-over-year; for FY2025, it was $53.1 million, down 41.6% from FY2024.

• Annual Non Operating Interest Expenses shows a five-year compound annual growth rate of 7.7% (FY2020 to FY2025).
• In prior years, BridgeBio Pharma's Non Operating Interest Expenses was $90.99 million in FY2024 (+11.9%), $81.29 million in FY2023 (+1.1%), $80.44 million in FY2022 (+72.0%) and $46.78 million in FY2021 (+27.6%).
• The Q2 2026 figure stands as the highest quarterly Non Operating Interest Expenses since Q1 2025.
• On a year-over-year basis, Non Operating Interest Expenses increased in three of the last eight quarters, with an average decline of 20.2%.
• The strongest year-over-year quarter for Non Operating Interest Expenses in the past five years was Q1 2022, with growth of 108.9%; the weakest was Q2 2025, with a decline of 49.4%.
• According to Business Quant data, Non Operating Interest Expenses for the three prior quarters was $12.94 million (Q1 2026), $11.64 million (Q4 2025) and $11.74 million (Q3 2025).